Efficacy of oral levofloxacin monotherapy against low-risk FN in                    patients with malignant lymphoma who received chemotherapy using the CHOP                    regimen

Ai Mogi; Hidenori Sasaki; Yuta Nakashima; Shotaro Chinen; Masanao Ishizu; Toshihiro Tanaka; Tohru Takata; Yasushi Takamatsu

doi:10.3960/jslrt.20008

Original Articles

Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen

Ai Mogi , Hidenori Sasaki, Yuta Nakashima, Shotaro Chinen, Masanao Ishizu, Toshihiro Tanaka, Tohru Takata, Yasushi Takamatsu

Author information

Ai Mogi Corresponding author
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Hidenori Sasaki
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Yuta Nakashima
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Shotaro Chinen
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Masanao Ishizu
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Toshihiro Tanaka
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Tohru Takata
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Yasushi Takamatsu
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan

Keywords: febrile neutropenia, levofloxacin, malignant lymphoma, CHOP

JOURNAL OPEN ACCESS

2020 Volume 60 Issue 3 Pages 73-77

DOI https://doi.org/10.3960/jslrt.20008

Browse “Advance online publication” version

Details

Abstract

The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retrospectively investigated the efficacy of LVFX against low-risk FN in patients with malignant lymphoma at our institution. Treatment success was defined as recovery from fever and neutropenia without alteration of the initial regimen. We recruited 29 patients between January 2013 and December 2018. The median age of the cohort was 64 (range: 21–87) years; 13 (44.8%) were aged over 65 years. In total, 22 patients had diffuse large B-cell lymphoma (DLBCL). Therapy was successful in 24 (82.8%) patients, whereas 5 had treatment failure requiring a change from LVFX to intravenous broad-spectrum antibacterial agents. No deaths related to FN were observed. Two patients required FN-related chemotherapy dose reduction in subsequent cycles. Although this cohort comprised many elderly patients, our study confirmed the efficacy of LVFX in patients with low-risk FN. This may improve the treatment of low-risk FN and malignant lymphoma.

Corresponding author